Renaissance Global Science & Tech Cl O (ATL1745)
223.03
+1.89 (+0.86%)
CAD |
May 24 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| -- | 216.20M | 0.00% | 87.73% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| 5.561M | -12.37% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The fund seeks to obtain long-term capital appreciation by investing in a diversified portfolio of global companies involved mainly in telecommunications, biotechnology, computer hardware and software, and medical services and other scientific and technology based companies. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ATL1027 |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Global Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CIBC Asset Management Inc |
| Prospectus Benchmark Index | |
| MSCI World/Information Tech NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Michal Marszal | 4.81 yrs |
| Craig Jerusalim | 3.01 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
47
5.561M
-534.39M
Category Low
4.218B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 24, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 24, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Microsoft Corp | 9.34% | 258.52 | -0.42% |
| Alphabet Inc Class A | 7.18% | 2106.51 | -0.61% |
|
Novartis AG
|
4.43% | -- | -- |
| Mastercard Inc Class A | 4.31% | 342.51 | 0.53% |
| UnitedHealth Group Inc | 4.20% | 497.49 | -0.01% |
|
Sanofi SA
|
4.07% | -- | -- |
| Apple Inc | 3.91% | 139.53 | -0.59% |
| CVS Health Corp | 3.89% | 97.38 | 0.96% |
| Medtronic PLC | 3.88% | 105.59 | 0.00% |
|
Takeda Pharmaceutical Co Ltd
|
3.68% | -- | -- |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Performance Fee | -- |
| Switching Fee | Upgrade |
| Transaction Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
Basic Info
| Investment Strategy | |
| The fund seeks to obtain long-term capital appreciation by investing in a diversified portfolio of global companies involved mainly in telecommunications, biotechnology, computer hardware and software, and medical services and other scientific and technology based companies. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ATL1027 |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Global Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CIBC Asset Management Inc |
| Prospectus Benchmark Index | |
| MSCI World/Information Tech NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Michal Marszal | 4.81 yrs |
| Craig Jerusalim | 3.01 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-24-22) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 0.0396 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of April 30, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 1/2/2001 |
| Last Annual Report Date | 8/31/2021 |
| Last Prospectus Date | -- |
| Share Classes | |
| ATL1027 | Commission-based Advice |
| ATL1227 | -- |
| ATL1637 | -- |
| ATL1645 | Fee-based Advice |
| ATL6737 | -- |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |